[Electrophysiologic effects of penticainide in patients with supraventricular tachycardia].
The electrophysiologic effects of the new class-I antiarrhythmic drug pentisomide were investigated after intravenous (5 mg/kg) application in nine patients with atrioventricular nodal reentrant tachycardia and six patients with atrioventricular tachycardia. Pentisomide did not change sinus cycle length, effective refractory period of the right ventricle (ERP-RV), the AV-node (ERP-AVN) and QT interval. Intranodal (AH-interval) and infranodal conduction time (HV-interval), effective refractory period of the right atrium (ERP-A), QRS duration, antegrade effective refractory period of the accessory pathway (ERP-Kent), ventricular cycle length during atrial fibrillation and tachycardia cycle length were significantly (P less than 0.05) increased. Intravenous pentisomide prevented induction of the tachycardia in 5/9 patients with atrioventricular nodal tachycardia and in 2/6 patients with atrioventricular tachycardia. The electrophysiologic properties of pentisomide indicate that it might be a useful drug in the treatment of supraventricular tachycardia.
Kühlkamp
V
V
Medizinische Klinik Abt. III, Eberhard-Karls-Universität, Tübingen.
Mewis
C
C
Mayer
F
F
Seipel
L
L
D000328:Adult; D000889:Anti-Arrhythmia Agents; D002304:Cardiac Pacing, Artificial; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011437:Propylamines / Q000008:administration & dosage*; D011725:Pyridines; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000188:drug therapy; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D011437:Propylamines; D011725:Pyridines; C045930:propisomide
Elektrophysiologische Effekte von Pentisomid bei Patienten mit supraventrikulärer Tachykardie.